Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686

SARS‐CoV‐2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup

Stadlbauer, D., Amanat, F., Chromikova, V., Jiang, K., Strohmeier, S., Arunkumar, G. A., Tan, J., Bhavsar, D., Capuano, C., Roubidoux, E. K., et al. (2020) · Current Protocols in Microbiology · doi:10.1002/cpmc.100 · Cited by 635

Disappearance of Antibodies to SARS-Associated Coronavirus after Recovery

Cao, W.-C., Liu, W., Zhang, P.-H., Zhang, F., & Richardus, J. H. (2007) · New England Journal of Medicine · doi:10.1056/nejmc070348 · Cited by 367

Living on Three Time Scales: The Dynamics of Plasma Cell and Antibody Populations Illustrated for Hepatitis A Virus

Andraud, M., Lejeune, O., Musoro, J. Z., Ogunjimi, B., Beutels, P., & Hens, N. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002418 · Cited by 75

Longitudinal Analysis of Severe Acute Respiratory Syndrome (SARS) Coronavirus-Specific Antibody in SARS Patients

Chang, S., Wang, J., Huang, L., Chen, Y., Fang, C., Sheng, W., Wang, J., Yu, C., & Yang, P. (2005) · Clinical and Vaccine Immunology · doi:10.1128/cdli.12.12.1455-1457.2005 · Cited by 32

A lateral flow test detecting SARS-CoV-2 neutralizing antibodiesPreprint

Zhang, N., Chen, S., Wu, J. V., Yang, X., & Wang, J. J. (2020) · medRxiv · doi:10.1101/2020.11.05.20222596 · Cited by 5

Incidence of SARS-CoV-2 infection among asymptomatic frontline health workers in Los Angeles County, CaliforniaPreprint

Halbrook, M., Gadoth, A., Martin‐Blais, R., Grey, A., Contreras, D. A., Kashani, S., Kazan, C., Kane, B., Tobin, N. H., Fulcher, J. A., et al. (2020) · medRxiv · doi:10.1101/2020.11.18.20234211 · Cited by 5

People Living with HIV Easily lose their Immune Response to SARS-CoV-2: Result From A Cohort of COVID-19 Cases in Wuhan, ChinaPreprint

Liu, Y., Xiao, Y., Wu, S., Marly, G., Ming, F., Wang, X., Wu, M., Feng, L., Tang, W., & Liang, K. (2021) · Research Square · doi:10.21203/rs.3.rs-543375/v1 · Cited by 5

People Living with HIV Easily Lose Their Immune Response to SARS-CoV-2: Result from a Cohort of COVID-19 Cases in Wuhan, ChinaPreprint

Xiao, Y., Wu, S., Marly, G., Ming, F., Wu, M., Tang, W., & Liang, K. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3774187 · Cited by 5

Humoral waning kinetics against SARS-CoV-2 is dictated by disease severity and vaccine platformPreprint

Tong, X., Kellman, B. P., Avendaño, M. J., Mendu, M., Hsiao, J. C., Serrano, E. F., García‐Salum, T., Muena, N. A., Pardo‐Roa, C., Morales, M., et al. (2024) · medRxiv · doi:10.1101/2024.10.17.24315607 · Cited by 5

Infection in asymptomatic carriers of SARS-CoV-2 can interfere with the achievement of robust immunity on a population scale

Viana, K. F., Zarpelon, L. F. B., Leandro, A., Terêncio, M. L., Lopes, R. D., Martins, C. A., Silva, I., Sibim, A. C., Marques, F., SILVA, R. D., et al. (2021) · Journal of General Virology · doi:10.1099/jgv.0.001684 · Cited by 4

Convalescent plasma for COVID ‐19: Donor demographic factors associated high neutralising antibody titres

Mehew, J., Johnson, R., Roberts, D. J., Griffiths, A., & Harvala, H. (2022) · Transfusion Medicine · doi:10.1111/tme.12868 · Cited by 4

Dynamic Analysis of a COVID-19 Vaccination Model with a Positive Feedback Mechanism and Time-Delay

Ai, X., Liu, X., Ding, Y., & Li, H. (2022) · Mathematics · doi:10.3390/math10091583 · Cited by 4

Time-dependent contraction of the SARS-CoV-2–specific T-cell responses in convalescent individuals

Fernandes, E. R., Apostólico, J. D. S., Jacintho, L. C., Marin, M. L. C., Júnior, R. C. V. D. S., Rodrigues, H., Santos, K. S., Coelho, V. P. C. V., Boscardin, S. B., Kalil, J. E., et al. (2022) · Journal of Allergy and Clinical Immunology Global · doi:10.1016/j.jacig.2022.05.002 · Cited by 4

Population-based study of the durability of humoral immunity after SARS-CoV-2 infection

Peterhoff, D., Wiegrebe, S., Einhauser, S., Patt, A. J., Beileke, S., Günther, F., Steininger, P. A., Niller, H. H., Burkhardt, R., Küchenhoff, H., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1242536 · Cited by 4

Comparative reconstruction of SARS-CoV-2 transmission in three African countries using a mathematical model integrating immunity data

Naffeti, B. S., Aribi, W. B., Kebir, A., Diarra, M., Schoenhals, M. J., Vigan-Womas, I., Dellagi, K., & Miled, S. B. (2023) · IJID Regions · doi:10.1016/j.ijregi.2023.11.011 · Cited by 4

Persistence of SARS-CoV-2-antibodies against N, S and RBD after natural infection

Jafari, M., Asli, S., Moghbeli, F., Fesharaki, M. G., Hajiahmadi, N., Mojtahedzadeh, F., Jamehdar, S. A., & Bamdad, T. (2023) · Iranian Journal of Microbiology · doi:10.18502/ijm.v15i6.14161 · Cited by 6

Comparative Analysis of Primary and Monovalent Booster SARS-CoV-2 Vaccination Coverage in Adults with and without HIV in Catalonia, Spain

Nomah, D. K., Reyes‐Urueña, J., Alonso, L., Díaz, Y., Moreno‐Fornés, S., Aceitón, J., Bruguera, A., Martín-Iguacel, R., Imaz, A., Gutiérrez, M. D. M., et al. (2023) · Vaccines · doi:10.3390/vaccines12010044 · Cited by 4

Dynamics of cytokine and antibody responses in community versus hospital SARS-CoV-2 infections

Singh, T., Macintyre, A. N., Burke, T. W., Anderson, J. G., Petzold, E., Stover, E. L., French, M. J., Oguin, T. H., DeMarco, T., McClain, M. T., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1468871 · Cited by 5

Pre-vaccination immune response to COVID-19 in a population in Northeast Portugal

Duro, M., Duro, I., Rebelo, I., Moreno, F., Pires, M., Jacinto, S., Pimentel, M., & Almeida, C. (2021) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-021-02799-6 · Cited by 4

A cross-sectional follow up study to estimate seroprevalence of coronavirus disease 2019 in Kobe, Japan

Doi, A., Iwata, K., Kuroda, H., Hasuike, T., Nasu, S., Nishioka, H., Tomii, K., Morimoto, T., & Kihara, Y. (2021) · Medicine · doi:10.1097/md.0000000000028066 · Cited by 4

Long-term immune responses in patients with confirmed novel coronavirus disease-2019: a 9-month prospective cohort study in Shanghai, China

Gong, X., Cui, P., Wu, H., Pān, H., Teng, Z., Yuan, F., Mao, S., Kong, D., Han, R., Zhao, X., et al. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07173-0 · Cited by 4

SARS‐CoV‐2 antibody seroprevalence rates among Egyptian blood donors around the third wave: Cross‐sectional study

El-Desoukey, N. A., Gaafar, T., Enein, A. A., Eyada, I. K., Khirat, S., ElShahawy, A., Diaa, N., & Youssry, I. (2022) · Health Science Reports · doi:10.1002/hsr2.634 · Cited by 6

Protective antigenic epitopes revealed by immunosignatures after three doses of inactivated SARS-CoV-2 vaccine

Peng, M., Dou, X., Zhang, X., Yan, M., Xiong, D., Jiang, R., Ou, T., Tang, A., Yu, X., Zhu, F., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.938378 · Cited by 4

Impact of SARS-CoV-2-specific memory B cells on the immune response after mRNA-based Comirnaty vaccine in seronegative health care workers

Vallejo, A., Vizcarra, P., Martín-Hondarza, A., Gómez-Maldonado, S., Häemmerle, J., Velasco, H., & Casado, J. L. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1002748 · Cited by 4

Longitudinal Observation of Immune Response for 23 Months in COVID-19 Convalescent Patients After Infection and Vaccination

Xu, J., Zheng, J., Tan, Y., Cai, J., Xiang, Y., Ling, H., Li, Z., & Bai, Q. (2023) · Viral Immunology · doi:10.1089/vim.2022.0111 · Cited by 4

Follow up and comparative assessment of IgG, IgA, and neutralizing antibody responses to SARS-CoV-2 between mRNA-vaccinated naïve and unvaccinated naturally infected individuals over 10 months

Younes, S. N., Nicolai, E., Al‐Sadeq, D. W., Younes, N., Al-Dewik, N. I. E., Abou-Saleh, H., Halawa, B. Y. A., Eid, A. H., Pieri, M., Liu, N., et al. (2023) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2023.08.009 · Cited by 4

Convalescent Plasma: An Evidence-Based Old Therapy to Treat Novel Coronavirus Patients

Kumar, S., Devi, C., Sarkar, S., Garg, V. K., Choudhary, P., Chopra, M., Sharma, V., & Prakash, R. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.97073 · Cited by 4

Seroprevalence of SARS-CoV-2 specific IgG antibodies among eye care workers in South India

Karthikeyan, R. S. G., Rameshkumar, G., Priya, C. G., Lalitha, P., Devi, R., Mani, I., & Ravindran, R. D. (2021) · Indian Journal of Medical Microbiology · doi:10.1016/j.ijmmb.2021.06.014 · Cited by 4

Lower seroprevalence for SARS‐CoV‐2‐specific antibodies among kidney transplant recipients compared to the general population in the city of Sao Paulo, Brazil

Cristelli, M. P., Viana, L. A., Fortaleza, C. M. C. B., Granato, C. F. H., Nakamura, M. R., Santos, D. W. D. C. L., Foresto, R. D., Junior, H. T. S., & Medina-Pestana, J. O. (2021) · Transplant Infectious Disease · doi:10.1111/tid.13706 · Cited by 5

SARS COV-2 anti-nucleocapsid and anti-spike antibodies in an emergency department healthcare worker cohort: September 2020 – April 2021

Wang, R. C., Murphy, C. E., Kornblith, A. E., Hohenstein, N. A., Carter, C. M., Wong, A. H. K., Kurtz, T. W., & Kohn, M. A. (2022) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2022.01.055 · Cited by 4

Vaccination with BNT162b2 and ChAdOx1 nCoV-19 Induces Cross-Reactive Anti-RBD IgG against SARS-CoV-2 Variants including Omicron

Gerges, D., Kapps, S., Hernández-Carralero, E., Freire, R., Aiad, M., Schmidt, S., Winnicki, W., Reiter, T., Pajenda, S., Schmidt, A., et al. (2022) · Viruses · doi:10.3390/v14061181 · Cited by 5

Radioligand Assay-Based Detection of Antibodies against SARS-CoV-2 in Hospital Workers Treating Patients with Severe COVID-19 in Japan

Matsunaga, H., Makino, A., Kato, Y., Murakami, T., Yamaguchi, Y., Kumanogoh, A., Oba, Y., Fujimi, S., Honda, T., & Tomonaga, K. (2021) · Viruses · doi:10.3390/v13020347 · Cited by 4

SECCION III. Clasificación clínica de casos y estratificación del riesgo de infección por SARS-CoV-2/COVID-19

Trujillo, C. H. S. (2021) · Infectio · doi:10.22354/in.v25i4.973 · Cited by 4

What is the long‐term clinical significance of anti‐SARS‐CoV‐2‐specific IgG?

Alberca, G. G. F., & Alberca, R. W. (2020) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12825 · Cited by 4

SARS-CoV-2 Antibody Testing: Important but Imperfect

Stapleton, J. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1755 · Cited by 4

Individuals With Less Severe Manifestations of SARS-CoV-2 Infection May Not Develop Long-Lasting Humoral Immunity

Murphy, P. T. (2020) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqaa233 · Cited by 4

Associating SARS-CoV-2 Serological Assays with Protection: Where the Field Stands

Tang, M. S., & Farnsworth, C. W. (2021) · Clinical Chemistry · doi:10.1093/clinchem/hvab039 · Cited by 4

Self-assessment of COVID-19 vaccination efficacy using a lateral flow tests for SARS-CoV-2 S1 protein antibodyPreprint

Li, M., Shan, Y., Cai, K., Ren, W., Sun, H., Wu, S., Li, J., Hong, D., Zhang, Z., Wang, Q. M., et al. (2021) · medRxiv · doi:10.1101/2021.06.27.21258591 · Cited by 4

SARS-COV-2 NSP5 Antagonizes MHC II Expresion by Subverting Histone Deacetylase 2Preprint

Taefehshokr, N., Lac, A., Vrieze, A. M., Dickson, B. H., Guo, P. N., Jung, C., Blythe, E. N., Fink, C., Aktar, A., Dikeakos, J. D., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.10.528032 · Cited by 4

Precision-Engineered Dermatan Sulfate-Mimetic Glycopolymers for Multi-Targeted SARS-CoV-2 Inhibition

Wang, L., Gao, L., Yang, C., Yin, M., Sun, J., Yang, L., Liu, C., Hinkley, S. F. R., Yu, G., & Cai, C. (2025) · Marine Drugs · doi:10.3390/md23120486 · Cited by 3

Prolonged SARS‐Cov‐2 shedding with rapid IgG antibody decay in a COVID‐19 patient: A case report

Huang, J., Lan, C., Wang, X., & Huang, M. (2021) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24002 · Cited by 3

A Prospective Study of the Serological, Clinical, and Epidemiological Features of a SARS-CoV-2 Positive Pediatric Cohort

Caballero, I. C., Ruedas-López, A., Berzosa, A., Ramos, M. I., Abancens, B. J., Bodas-Pinedo, A., Guillén-Martín, S., Sánchez, B. S., García-Bermejo, I., Arana, D. M., et al. (2022) · Children · doi:10.3390/children9050665 · Cited by 3

A retrospective study showing a high rate of seropositivity against SARS-CoV-2 in wild felines in India

Borkakoti, R., Karikalan, M., Nehul, S., Jogi, H. R., Sharma, K., Nautiyal, S., Mishra, R., Mahajan, S., Biswas, S. K., Nandi, S., et al. (2023) · Archives of Virology · doi:10.1007/s00705-023-05735-4 · Cited by 3

Post-acute sequelae of COVID-19 and longitudinal antibody levels in a community-based cohort

Kopplin, N. G., Garcia, A., Reczek, A., Wilkinson, K., Yekkaluri, S., Murphy, C. C., Tiro, J. A., Muthukumar, A. R., Masica, A. L., & Singal, A. G. (2023) · PLoS ONE · doi:10.1371/journal.pone.0291259 · Cited by 4

T‐cell responses in COVID‐19 survivors 6−8 months after infection: A longitudinal cohort study in Pune

Suryawanshi, P. V., Patil‐Takbhate, B., Athavale, P. V., MIRZA, S. B., Tripathy, A. S., Kanitkar, S. A., Shivnitwar, S. K., Barthwal, M. S., Dole, S. S., Chavan, H., et al. (2024) · Immunity Inflammation and Disease · doi:10.1002/iid3.1238 · Cited by 3

Seroprevalence of SARS-CoV-2 and risk factors for infection among children in Uganda: A serial cross-sectional study

Bagala, I., Namuganga, J. F., Nayebare, P., Cuu, G., Katairo, T., Nabende, I., Gonahasa, S., Nassali, M., Tukwasibwe, S., Dorsey, G., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0312554 · Cited by 3

Time course and determinants of the antibody response to SARS-CoV-2 in Costa Rica: the RESPIRA study

Herrero, R., Fantin, R., Loría, V., Aparicio, A., Prevots, D. R., Zúñiga, M., Wong, R., Morera, M., Butt, J., Binder, M., et al. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-10742-8 · Cited by 3

Review of SARS-CoV-2 Antigen and Antibody Testing in Diagnosis and Community Surveillance

Nerenz, R. D., Hubbard, J. A., & Cervinski, M. A. (2021) · Advances in Molecular Pathology · doi:10.1016/j.yamp.2021.06.008 · Cited by 3

Second round statewide sentinel-based population survey for estimation of the burden of active infection and anti-SARS-CoV-2 IgG antibodies in the general population of Karnataka, India, during January-February 2021

Padma, M. R., Dinesh, P., Sundaresan, R., Athreya, S., Shiju, S., Maroor, P. S., Hande, R. L., Akhtar, J., Chandra, T., Deepa, R., et al. (2021) · IJID Regions · doi:10.1016/j.ijregi.2021.10.008 · Cited by 3

Serological Evaluation of Patients with Coronavirus Disease-2019 in Daegu, South Korea

Park, S., Chang, S. H., Lee, J. H., Lee, J. H., Ham, J. Y., Kim, Y. K., Kim, S.-G., & Ryoo, N. H. (2020) · PLoS ONE · doi:10.1371/journal.pone.0262820 · Cited by 3

Humoral and cellular immune response levels at a 1-year follow-up after mild COVID-19

Flieder, T., Fischer, B., von Bargen, K., Peter, A., Knabbe, C., & Birschmann, I. (2022) · Journal of Clinical Virology · doi:10.1016/j.jcv.2022.105236 · Cited by 3

Estimating the Effectiveness of Shielding during Pregnancy against SARS-CoV-2 in New York City during the First Year of the COVID-19 Pandemic

Chen, S., Murphy, E. A., Pendergrass, A. G., Sukhu, A. C., Eng, D., Jurkiewicz, M., Mohammed, I. A., Rand, S., White, L. J., Hupert, N., et al. (2022) · Viruses · doi:10.3390/v14112408 · Cited by 3

Assessment of Reactivity to the Administration of the mRNA Vaccine after Six Months of Observation

Słomka, S., Zięba, P., Rosiak, O., & Piekarska, A. (2023) · Vaccines · doi:10.3390/vaccines11020366 · Cited by 4

Epitope Coverage of Anti-SARS-CoV-2 Nucleocapsid IgA and IgG Antibodies Correlates with Protection against Re-Infection by New Variants in Subsequent Waves of the COVID-19 Pandemic

Mullins, M. O., Smith, M., Maboreke, H., Nel, A. J. M., Ntusi, N., Burgers, W. A., & Blackburn, J. M. (2023) · Viruses · doi:10.3390/v15020584 · Cited by 3

Systems biology of B cells in COVID-19

Woodruff, M. C., Faliti, C. E., & Sanz, I. (2024) · Seminars in Immunology · doi:10.1016/j.smim.2024.101875 · Cited by 3

Reactivity of anti‐SARS‐CoV ‐2 antibodies in Serbian voluntary blood donors

Bezanovic, M., Budakov-Obradović, Z., Bujandrić, N., Kocic, N., Krga-Milanovic, M., Majkić, M., Obrovski, B., & Grujić, J. (2024) · Transfusion Medicine · doi:10.1111/tme.13034 · Cited by 3

Dynamics of SARS-CoV-2 antibodies after natural infection: insights from a study on Pasteur Institute of Tunis employees

Cherif, I., Kharroubi, G., Darragi, I., Benna, S. E., Gharbi, A., Baccouche, A., Souissi, C., Bahri, O., Ahmed, M. B., & Bettaieb, J. (2024) · Libyan Journal of Medicine · doi:10.1080/19932820.2024.2348233 · Cited by 3

Cellular and humoral immunogenicity against SARS-CoV-2 vaccination or infection is associated with the memory phenotype of T- and B-lymphocytes in adult allogeneic hematopoietic cell transplant recipients

Konuma, T., Hamatani‐Asakura, M., Nagai, E., Adachi, E., Kato, S., Isobe, M., Monna‐Oiwa, M., Takahashi, S., Yotsuyanagi, H., & Nannya, Y. (2024) · International Journal of Hematology · doi:10.1007/s12185-024-03802-3 · Cited by 3

Vitamin D as an Adjuvant Immune Enhancer to SARS-Cov-2 Vaccine

Salamony, A., Abdelsalam, M., Elguindy, N., Roshdy, W. H., Youssef, A., & Shamikh, Y. I. (2025) · Current Microbiology · doi:10.1007/s00284-025-04095-3 · Cited by 3

Antibody Dynamics, Seroreversion, and Persistence After Severe Acute Respiratory Syndrome Coronavirus 2: Another Answer

Poland, G. A. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab243 · Cited by 3

A Glimpse into the Diverse Cellular Immunity against SARS-CoV-2

Chang, C., Liu, Y., Jiao, C., Liu, H., Gong, J., Chen, X., & Chang, L. (2021) · Vaccines · doi:10.3390/vaccines9080827 · Cited by 3

Rapid and Laboratory SARS-CoV-2 Antibody Testing in High-Risk Hospital Associated Cohorts of Unknown COVID-19 Exposure, a Validation and Epidemiological Study After the First Wave of the Pandemic

O’Kelly, B., McLaughlin, R. A., O’Doherty, R., Carroll, H. K., Murray, R., Dilworth, R., Corkery, L., Cotter, A. G., McGinty, T., Muldoon, E. G., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.642318 · Cited by 3

COVID-19: Lesson Learnt from Diagnostics to Therapeutics

Panda, P. K., Chavda, V. P., Neve, K., Mishra, S., Verma, S. K., & Ahuja, R. (2022) · Springer eBooks · doi:10.1007/978-981-19-3979-2_16 · Cited by 4

Humoral and cellular responses to repeated COVID-19 exposure in multiple sclerosis patients receiving B-cell depleting therapies: a single-center, one-year, prospective study

Alfonso, R., Lin, J., Lei, J., Liu, J., Roche, M., Oliveira, A. D., Raisingani, A., Kumar, A., Kirschner, V., Feuer, G., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1194671 · Cited by 3

SARS-CoV-2 Infection among Medical Institution Faculty and Healthcare Workers in Tokyo, Japan

Nishimura, T., Uwamino, Y., Uno, S., Kashimura, S., Shiraki, T., Kurafuji, T., Morita, M., Noguchi, M., Azegami, T., Yamada-Goto, N., et al. (2021) · Internal Medicine · doi:10.2169/internalmedicine.7033-21 · Cited by 3

Antiviral Immunity in SARS-CoV-2 Infection: From Protective to Deleterious Responses

Mihăescu, G., Chifiriuc, M. C., Vrâncianu, C. O., Constantin, M., Filip, R., Popescu, M. R., Burlibaşa, L., Nicoară, A. C., Bolocan, A., Iliescu, C., et al. (2021) · Microorganisms · doi:10.3390/microorganisms9122578 · Cited by 3

RapidQ: A reader-free microfluidic platform for the quantitation of antibodies against the SARS-CoV-2 spike protein

Mattila, J., Amaro, A., Longo, M., Antaki, J. F., Koirala, S., & Gandini, A. (2022) · Biomicrofluidics · doi:10.1063/5.0079054 · Cited by 3

Prevalence of SARS-CoV-2 infection among obstetric patients in Ottawa, Canada: a descriptive study

Fakhraei, R., Erwin, E., Alibhai, K. M., Murphy, M. S. Q., Dingwall‐Harvey, A. L. J., White, R. R., Dimanlig-Cruz, S., LaRose, R., Grattan, K. P., Jia, J., et al. (2022) · CMAJ Open · doi:10.9778/cmajo.20210228 · Cited by 3

Review of SARS-CoV-2 Antigen and Antibody Testing in Diagnosis and Community Surveillance

Nerenz, R. D., Hubbard, J. A., & Cervinski, M. A. (2022) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2022.09.018 · Cited by 5

Durability of Viral Neutralization in Asymptomatic Coronavirus Disease 2019 for at Least 60 Days

Haymond, A. N., Damluji, A. A., Narayanan, A., Mueller, C., Reeder, A., Alem, F., Maxwell, G. L., Petricoin, E. F., Liotta, L. A., & deFilippi, C. R. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab140 · Cited by 3

Recurrent COVID-19 in Hemodialysis: A Case Report of 2 Possible Reinfections

Krishna, V. N., Ahmad, M., Overton, E. T., & Jain, G. (2021) · Kidney Medicine · doi:10.1016/j.xkme.2021.02.004 · Cited by 3

Low SARS-CoV-2 seroprevalence but high perception of risk among healthcare workers at children’s hospital before second pandemic wave in Germany

Neumann, M., Aigner, A., Rossow, E., Schwarz, D., Marschallek, M., Steinmann, J., Stücker, R., Königs, I., & Stock, P. (2021) · World Journal of Pediatrics · doi:10.1007/s12519-021-00447-8 · Cited by 3

Severe Acute Respiratory Syndrome Coronavirus 2: Manifestations of Disease and Approaches to Treatment and Prevention in Humans

Watson, M. E., Inagaki, K., & Weinberg, J. B. (2021) · Comparative Medicine · doi:10.30802/aalas-cm-21-000011 · Cited by 3

Longevity of seropositivity and neutralizing titers among SARS-CoV-2 infected individuals after 4 months from baseline: a population-based study in the province of TrentoPreprint

Stefanelli, P., Bella, A., Fedele, G., Fiore, S., Pancheri, S., Benedetti, E., Fabiani, C., Leone, P., Vacca, P., Schiavoni, I., et al. (2020) · medRxiv · doi:10.1101/2020.11.11.20229062 · Cited by 3

Understanding the Challenges and Uncertainties of Seroprevalence Studies for SARS-CoV-2Preprint

McConnell, D. J., Hickey, C., Bargary, N., Trela-Larsen, L., Walsh, C., Barry, M. G., & Adams, R. (2020) · Preprints.org · doi:10.20944/preprints202012.0126.v1 · Cited by 3

Population Changes in Seroprevalence among a Statewide Sample in the United StatesPreprint

Malecki, K. M. C., Nikodémová, M., Schultz, A., Bersch, A. J., Walsh, M. C., Sethi, A. K., Peppard, P. E., Engelman, C. D., Cadmus‐Bertram, L., Safdar, N., et al. (2020) · medRxiv · doi:10.1101/2020.12.18.20248479 · Cited by 2

Detection and Quantification of Antibody to SARS-CoV-2 Receptor Binding Domain Provides Enhanced Sensitivity, Specificity and UtilityPreprint

Tedder, R. S., Parker, E. L., Sureda-Vives, M., Fernández, N., Randell, P. A., Marchesin, F., Katsanovskaja, K., Harvey, R., Lilley, A., Harris, B. H. L., et al. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3739821 · Cited by 3

Diclofenac potassium/Nitazoxanide/Azithromycin Used in Adults, Children and Pregnant Patients: A Novel Potential Game Changer COVID-19 Protocol.Preprint

Kelleni, M. T. (2021) · doi:10.31219/osf.io/vmq3y · Cited by 3

Differential Kinetics of T Cell and Antibody Responses Delineate Dominant T Cell Epitopes in Long-Term Immunity after COVID-19Preprint

Bilich, T., Nelde, A., Heitmann, J. S., Maringer, Y., Roerden, M., Bauer, J., Rieth, J., Wacker, M., Peter, A., Hörber, S., et al. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3713528 · Cited by 2

Factors associated with release relief of Long COVID symptoms at 12-Months and their impact on daily lifePreprint

Salmon, D., Slama, D., Linard, F., Dumesges, N., Baut, V. L., Hakim, F., Oustric, P., Seyrat, E., Thoreux, P., & Marshall, E. (2022) · medRxiv · doi:10.1101/2022.11.18.22282459 · Cited by 3

Protection of hybrid immunity against SARS-CoV-2 reinfection and severe COVID-19 during periods of Omicron variant predominance in MexicoPreprint

Montes-González, J. A., Zaragoza-Jiménez, C. A., Antonio‐Villa, N. E., Fermín‐Martínez, C. A., Ramírez‐García, D., Vargas‐Vázquez, A., Gutiérrez‐Vargas, R., García-Rodríguez, G., López‐Gatell, H., Valdés‐Ferrer, S. I., et al. (2022) · medRxiv · doi:10.1101/2022.12.02.22282981 · Cited by 3

Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activityPreprint

van Dam, K. P. J., Volkers, A., Wieske, L., Stalman, E. W., Kummer, L. Y. L., van Kempen, Z. L. E., Killestein, J., Tas, S. W., Boekel, L., Wolbink, G., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2272601/v1 · Cited by 3

Seroprevalence of anti-SARS-CoV-2 antibodies and risk of viral exposure among healthcare workers in the South Kivu province, eastern Democratic Republic of the Congo: a cross-sectional study

Baharanyi, T. C., Cikwanine, J. P. B., Kribi, S., Yoyu, J. T., Hofmann, N., Grossegesse, M., Nitsche, A., Tomczyk, S. M., Vietor, A. C., Leendertz, F. H., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-072212 · Cited by 2

SARS-CoV-2 Nsp1 Is a Major Suppressor of HLA Class I and Class II Expression

Schirmeister, I., Eckert, N., Weigang, S., Fuchs, J., Kern, L., Kochs, G., & Halenius, A. (2025) · Viruses · doi:10.3390/v17081083 · Cited by 2

Antibody response after two doses of the SARS-CoV-2 Comirnaty vaccine in a Covid-19 positive and Covid-19 negative Italian healthcare workers cohort

Sulejmani, A., Giacobone, C., Spiti, S., Pozzobon, C., Dominici, R., Mascagni, P., Falbo, R., Brambilla, P., & Leoni, V. (2022) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2022.2034036 · Cited by 2

A case of COVID-19 reinfection in a hemodialysis patient: the role of antibody in SARS-CoV-2 infection

Beppu, H., Ogawa, T., Ishikane, M., Kawanishi, T., Fukuda, T., Sato, L., Matsunaga, A., Maeda, K., Katagiri, D., Ishizaka, Y., et al. (2022) · CEN Case Reports · doi:10.1007/s13730-022-00697-z · Cited by 2

Eight Months of Serological Follow-Up of Anti-SARS-CoV-2 Antibodies in France: A Study among an Adult Population

Decarreaux, D., Sevila, J., Masse, S., Capai, L., Fourié, T., Villarroel, P. M. S., Amroun, A., Nurtop, E., Vareille, M., Blanchon, T., et al. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192215257 · Cited by 2

Humoral and Cellular Immunity to Severe Acute Respiratory Syndrome Coronavirus-2 Vaccination in Patients with Sarcoidosis

Atahan, E., Öztürk, B. Ç., Akçin, R., Sarıbaş, S., & Kocazeybek, B. S. (2022) · Balkan Medical Journal · doi:10.4274/balkanmedj.galenos.2022.2022-8-64 · Cited by 2

Features of the Formation of Seroprevalence to SARS-CoV2 in the Population of the Republic of Tatarstan during the Spread of COVID-19

Решетникова, И. Д., Agafonova, E. V., Khakimov, N. M., Tyurin, Y. A., Шайхразиева, Н. Д., & Ziatdinov, V. B. (2023) · Epidemiology and Vaccinal Prevention · doi:10.31631/2073-3046-2023-22-1-13-21 · Cited by 2

Seroprevalence of IgM/IgG and Neutralizing Antibodies against SARS-CoV-2 in Unvaccinated Young Adults from Mexico Who Reported Not Having Had a Previous COVID-19 Infection

Padilla-Bórquez, D. L., Matuz-Flores, M. G., Hernández‐Bello, J., Sánchez‐Zuno, G. A., García‐Arellano, S., Oregon‐Romero, E., Herrera-Godina, M. G., González-Estévez, G., Adan-Bante, N. P., Rosas‐Rodríguez, J. A., et al. (2024) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2024/8871439 · Cited by 2

Investigating the diagnostic and prognostic value of anti-SARS-CoV-2 Spike IgG/IgM ELISA tests in patients infected with coronavirus Delta variant

Pouladzadeh, M., Hosseinzadeh, M., Khedri, R., Choghakabodi, P. M., Amini, P., bavani, A. G., Moghadam, H. B., Behmanesh, B., Delirrooyfard, A., Sokooti, A., et al. (2024) · Infezioni in Medicina · doi:10.53854/liim-3201-4 · Cited by 2

Kinetics of naturally induced binding and neutralising anti-SARS-CoV-2 antibody levels and potencies among SARS-CoV-2 infected Kenyans with diverse grades of COVID-19 severity: an observational study

Kimotho, J., Sein, Y., Sayed, S., Shah, R., Mwai, K., Saleh, M. N., Wanjiku, P., Mwacharo, J. K., Nyagwange, J., Karanja, H., et al. (2023) · Wellcome Open Research · doi:10.12688/wellcomeopenres.19414.1 · Cited by 2

Anti-SARS-CoV-2 Antibody Development over Four Years in Blood Donors

Niederhauser, C., Widmer, N., Tinguely, C., Suter‐Riniker, F., Fontana, S., Buser, A. S., Waldvogel, S., Thierbach, J., Züger, M., & Gowland, P. (2025) · Viruses · doi:10.3390/v17101292 · Cited by 2

Persistence of humoral and cellular immune response after SARS-CoV-2 infection: opportunities and challenges

Wu, T. (2020) · Frontiers of Medicine · doi:10.1007/s11684-020-0823-4 · Cited by 2

SARS-CoV-2 Serology Monitoring of a Cancer Center Staff in the Pandemic Most Infected Italian Region

Ciniselli, C. M., Micali, A., Cecco, L. D., Notti, P., Sinno, V., Luison, E., Melani, C. C., Daidone, M. G., Apolone, G., Verderio, P., et al. (2021) · Cancers · doi:10.3390/cancers13051035 · Cited by 2

Clinician guide to COVID-19 diagnostics

Iro, M. A., Umpleby, H., & Pelosi, E. (2021) · Archives of Disease in Childhood Education & Practice · doi:10.1136/archdischild-2020-321272 · Cited by 2

Clinical characteristics of COVID-19 in young patients differ from middle-aged and elderly patients

Wan, K.-Q., Su, C., Kong, L., Liao, J., Tian, W., & Luo, H. (2021) · Archives of Medical Science · doi:10.5114/aoms/133090 · Cited by 2

Coronaviruses in pregnant women in Saudi Arabia

Barry, M. A., & Barry, M. A. (2021) · Asian Pacific Journal of Reproduction · doi:10.4103/2305-0500.316621 · Cited by 2

Patterns of negative seroconversion in ongoing surveys of SARS-CoV-2 antibodies among workers in New York’s largest healthcare system

Sembajwe, G. N., Rasul, R., Jacobs, Y., Edwards, K., Lewis, L. C., Chang, T. Y., Lowe, W. L., & Moline, J. M. (2021) · Occupational and Environmental Medicine · doi:10.1136/oemed-2021-107382 · Cited by 2

Periodic Evaluation of Anti-SARS-CoV-2 Antibody Levels and Determination of Surrogate Virus Neutralization in Healthcare Workers with COVID-19

Tok, Y., Kuşkucu, M. A., Sarıbal, D., Yılmaz, S. S., Nohut, O. K., Aygün, G., & Midilli, K. (2021) · Mikrobiyoloji Bulteni · doi:10.5578/mb.20219704 · Cited by 2

SARS-CoV-2 seroprevalence in health care workers in a third level hospital in Turkey

Eser, E., Akar, Ş. Ş., Akçalı, S., Ecemiş, T., Dündar, P. E., Çiçek, K., Akman, D., Tüzün, E., ERKEKOĞLU, G. Ş., Buran, Z. C., et al. (2021) · Türkiye Halk Sağlığı Dergisi · doi:10.20518/tjph.981404 · Cited by 2

Natural immune response and protection from SARS-CoV-2 reinfection

Margiotti, K., Fabiani, M., Mesoraca, A., & Giorlandino, C. (2021) · Acta Virologica · doi:10.4149/av_2021_401 · Cited by 2

COVID-19 vaccine and immune response

Hıntıstan, S., & DEMİRAĞ, H. (2021) · Exploration of Immunology · doi:10.37349/ei.2021.00023 · Cited by 3

A Pragmatic Approach to Immunity & Respiratory Viral Infections.

Born, T. A. N. D. C. N. S. (2020) · Europe PMC (PubMed Central) · Cited by 2

Loss of Anti–SARS-CoV-2 Antibodies in Mild Covid-19

Bölke, E., Matuschek, C., & Fischer, J. C. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2027051 · Cited by 95

Rapid decline of neutralizing antibodies is associated with decay of IgM in adults recovered from mild COVID-19

Harrington, W. E., Trakhimets, O., Andrade, D. V., Dambrauskas, N., Raappana, A., Jiang, Y., Houck, J., Selman, W., Yang, A., Vigdorovich, V. I., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100253 · Cited by 65

Neutralizing Antibodies Against SARS-CoV-2—Important Questions, Unclear Answers

Katz, M. H. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.4624 · Cited by 6

Longitudinal anti-SARS-CoV-2 antibody profile and neutralization activity of a COVID-19 patient

Yin, S., Tong, X., Huang, A., Shen, H., Li, Y., Liu, Y., Wu, C., Huang, R., & Chen, Y. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.06.076 · Cited by 26

Longitudinal analysis of antibody decay in convalescent COVID-19 patients

Xia, W., Li, M., Wang, Y., Kazis, L. E., Berlo, K., Melikechi, N., & Chiklis, G. R. (2021) · Scientific Reports · doi:10.1038/s41598-021-96171-4 · Cited by 32